Skip to main content

Advertisement

Download PDF

Reasons why Thai patients with chronic kidney disease use or do not use herbal and dietary supplements

BMC Complementary and Alternative Medicine volume 14, Article number: 473 (2014) Cite this article

Abstract

Background

Despite a high prevalence of herbal and dietary supplement use (HDS) in pre-dialysis patients, the reasons are unknown as to why they decide to use HDS. Objectives of the cross-sectional and qualitative studies were to determine reasons for the use and non-use of HDS in Thai patients with chronic kidney disease (CKD).

Methods

This prospective study recruited 421 patients with stage 3–5 CKD from two kidney clinics in Thailand, and 357 were followed up regarding their HDS use over 12 months. Patients receiving renal replacement therapy at baseline were excluded. Participants were interviewed at baseline and in the twelfth month regarding their HDS use, and reasons for their use or non-use of HDS. Among HDS users, 16 patients were enrolled in a qualitative study and were interviewed using eight-open ended questions about reasons for HDS use. Descriptive and thematic analyses were performed.

Results

Thirty-four percent of patients with CKD consistently used HDS over the 12 months and 17% of all patients intermittently took them during the follow-up period. At baseline, family or friends’ recommendation was the most common reason for HDS use (35%), followed by having a perception of benefits from using HDS (24%). During the follow-up period, perceived benefits of HDS was a frequently reported reason for either continuing with HDS use (85%) or starting to use HDS (65%). Negative experience from using HDS influenced patients to stop using them (19%). Although the main reason for non-use of HDS was trust in a doctor or effectiveness of conventional medicine (32%), doubt about the benefits from HDS or concerns about negative effects were frequently reported reasons for non-use (23%). Doctor’s recommendations to avoid using HDS were the main influence for non-users (19%) and for those who had stopped using HDS (23%). The media and patients’ social network had an impact on HDS use.

Conclusions

Patients who perceived benefits from HDS use were more likely to use HDS, whilst non-users had negative attitudes towards HDS. Health professionals therefore should educate patients and their relatives about the risks and benefits from using HDS.

Peer Review reports

Background

Use of herbal and dietary supplements (HDS) has risen worldwide [1]. Patients with kidney diseases, such as chronic kidney disease, dialysis, and kidney transplantation, are more likely to use HDS (28%-57%) [2–5]. Most frequently reported reasons for using HDS or complementary and alternative medicine (CAM) in patient populations are the perception of their benefits and safety, dissatisfaction with conventional medicine, and willingness to try them [6–17]. Cross-sectional studies are the main information source reporting this issue, whilst there are limited qualitative studies [18–20]. Small numbers of surveys report reasons why patients are unlikely to use HDS or CAM, that is, doubt about their efficacy and safety, and satisfaction with conventional medicine [15, 21–23].

There are few surveys about reasons for HDS or CAM use amongst patients with kidney diseases [2, 4, 24]. They report that the perceived benefits and safety of HDS or CAM are the main reasons for their use. Shah et al. (2013) found CAM use was related to experiencing side effects from conventional medicine (OR 9.59, 95% CI 2.77-33.20), dissatisfaction with a doctor (OR 4.16, 95% CI 1.75-10.10) and belief in a holistic approach (OR 3.20, 95% CI 1.58-6.47) [24]. However, there is a lack of qualitative studies conducted exploring this issue further. Therefore in this paper, a combination of a survey and qualitative study aimed to ascertain reasons why patients with chronic kidney disease (CKD) use HDS. The secondary objective of the survey was to determine reasons for non-use of HDS. The patients were also followed up over 12 months in order to observe decision-making process in HDS use or non-use. These findings will guide health professionals into fully understanding of HDS use in these patients and prepare them to deal with this issue.

Methods

The survey

A prospective, cross-sectional study recruited 421 patients with stage 3–5 CKD from two kidney clinics at teaching hospitals in Thailand during January to June 2012. All patients, in both settings, were approached by MT or two trained interviewers, and informed about the project, and asked for their consent. Patients receiving renal replacement therapy before the recruitment were excluded. Fifteen patients did not meet the inclusion criteria due to three patients receiving dialysis and 12 patients having stage 2 CKD (estimated glomerular filtration rate of approximately 60–65 ml/min/1.73 m2). Of 406 patients recruited, 357 patients were followed up regarding their HDS use, and any perceived beneficial and detrimental effects of HDS over 12 months. Forty-nine patients left the study due to death (n = 30) or lost to follow-up (n = 19). Herbal and dietary supplements were defined as products containing plant-derived material, either raw or processed ingredients, from one or more plants, or containing dietary ingredients, such as vitamins, minerals, amino acids and substances, such as, enzymes, organ tissues, glands and metabolites [25, 26]. Ethical approval was obtained from the Institutional Review Board for Research in Human Subjects at Faculty of Medicine, Chulalongkorn University and Srinakharinwirot University in Thailand, and the Medical School Research Ethics Committee, University of Nottingham in the UK.

Patients were interviewed at baseline regarding their HDS use, information sources, and reasons for HDS use or non-use. The data collection was via a researcher-administered questionnaire, which was developed and validated by the authors [27]. The questionnaire used a mixture of previously validated and new questions. In the twelfth month, participants were interviewed over the telephone about their HDS use and reasons for continuing, stopping or starting HDS use since the baseline survey. Simple frequencies with percentages were used to determine reasons for HDS use and non-use.

The qualitative study

From the HDS users identified in the survey, the patients who had provided details of the reasons for HDS use were approached. If they consented to participate in the qualitative study, they were recruited. Patients were recruited and interviewed face-to-face until data saturation was reached (n = 16). Eight open-ended questions about their reasons for HDS use were developed based on literature, see Table 1[28, 29]. This interview was piloted and it was found that all participants (n = 6) understood and answered the questions fully. This questionnaire was administered using face-to-face interviews. The interviews lasted approximately 5–10 minutes and were audio recorded.

Table 1 The interview questions about reasons for HDS use
Full size table

The audio recordings were transcribed verbatim and the Thai transcripts were twice checked for accuracy against the recordings before starting the process of forward translation. Meaning-based translation from Thai language to English language was performed and English transcripts were twice checked with the Thai transcripts [30]. Then five out of the sixteen transcripts were backward translated by a bilingual person which found one error. This was rectified.

The transcripts were analysed by inductive thematic analysis with line-by-line coding [31, 32]. The Weft QDA, a software programme for qualitative data analysis, was used for assisting in the organisation of the transcripts [31, 32].

Results

Demographic characteristics of participants are shown in Table 2. Of 357 participants, 166 participants (46%) had used HDS together with conventional medicines in the last 12 months before the recruitment. Three patterns of HDS use were seen over the year: continuing users (34%, n = 123), non-users (49%, n = 177) and intermittent users (17%, n = 60).

Table 2 Demographic characteristics of respondents in the survey (n = 357) and qualitative study (n = 16)
Full size table

The most frequently reported reasons for HDS use in the survey were due to family or friends’ recommendations (35%), followed by the expectation of gaining benefit from using HDS (24%), see Table 3. Meanwhile, only 3% of users reported the safety of HDS as a reason for HDS use. Regarding the qualitative findings, five themes emerged on perceptions of HDS: patients’ health care needs; perceptions of benefit and safety of HDS; willingness to try HDS; and side effects of conventional medicine (CM). Additionally, two further themes influencing HDS use were recommendations from patients’ social network and the media, see Figure 1. Such influences were consistent with the findings from the survey; family, friends and the media were most frequently reported as HDS information sources, see Table 3. The main findings of the survey and qualitative study were similar, except that health professionals’ recommendation for HDS use and the ease of access to HDS were not found in the qualitative study.In the qualitative study, the media and the patients’ social network influenced patients to try HDS as they provided information about the benefits and safety of HDS (Figure 1). Participants also seemed to respect educated family members, friends and acquaintances, such as doctors, nurses, and teachers, so they complied with their recommendation to use HDS. Both the media and the social network provided limited information about the safety of HDS use in patients with CKD.

Table 3 Reasons for HDS use from both quantitative and qualitative studies at baseline
Full size table
Figure 1
figure1

Themes from interviews with 16 participants about their reasons for using HDS.

Full size image

… a herbal company advertises on television that the product is approved by the Thai FDA for a dietary supplement… A herbal company advertises “This herb is the best on sale product” “It is useful” “You would not be disappointed”. (R13, m age 70)

My younger brother confirmed that HDS is good and cleans the blood vessels, so blood circulation is improved. He said “You should take it” “It does no harm”. (R4, f age 56)

He [my older brother who has a wife working as a nurse and whose brother-in-law is a doctor] said “You should eat these herbs, they are good”. (R13, m age 70)

You know, there is marked lack of warning about taking herbs. (R11, f age 44)

However, some patients were concerned about renal adverse effects of HDS, so they tended to use HDS with caution and would consult with their health care providers if necessary.

If I take too many herbs, I’m afraid of worsening liver and kidney function. (R7, m age 67)

Patients’ desire to improve, or at least stabilise their condition was a drive for seeking alternative therapy, for example avoidance of receiving dialysis and being able to live their normal daily lives, such as being able to walk and cook. As a result, some patients actively sought HDS information, particularly about their benefits, and decided to use HDS by themselves. They experimented with HDS and monitored their effects. Where they noticed positive effects from using HDS, they would continue using them and where they did not, they would stop using them. Others wanted to integrate HDS into their mainstream treatment in order to increase the efficacy of the conventional treatment.

I’m afraid of receiving dialysis… I want to use everything, which helps me to avoid receiving dialysis. (R8, m age 67)

I have to learn about herbal information by myself and know about them from my colleagues’ or friends’ experiences of using herbs… I have to think whether or not herbs suit me and decide to use them by myself. (R11, f age 44)

I wanted to try them. After trying them, they were good. Thus, I continue to use them. (R1, f age 59)

Conventional medicines are more effective than any herbs. Herbs supplement conventional medicines. (R12, m age 75)

Some patients reported using HDS due to dissatisfaction with conventional medicine or had negative attitudes towards it.

I had lots of side effects from conventional medicines, so I turned my thoughts to herbal use and used it. (R5, m age 43)

I’m afraid of worsening kidney function. If I take lots of prescribed medicines, whether they will affect kidneys or not? (R9, f age 46)

Regarding the follow-up study, reasons for continuing or changing are shown in Table 4. The perception of benefits from using HDS was the main reason for consistent users (85%, n = 105) and new users (65%, n = 11). Amongst 73 patients who continued using HDS due to the benefits gained from using HDS, 31 patients (42%) reported that they relieved minor ailments, such as kariyat or vitamin C for the common cold, curcumin for flatulence, senna or ‘Ka Sai’ as a laxative, and ‘Ya Hom’ for dizziness. Twenty-five patients (34%) had used dietary supplements for well-being, and perceived such effects during the follow-up period. Examples of such products were ginseng, essence of chicken drink, fish oil, bee pollen, germ oil, swiftlet’s nest drink, and botanical extracts. Other benefits from using HDS are shown in Table 5. Neither negative experiences from HDS use (26%, n = 11) nor negative attitudes towards HDS (7%, n = 3) influenced continuing HDS use. Eight patients experienced negative effects from using HDS, see Table 5. Three patients perceived no benefit from using HDS, i.e. essence of chicken drink for tiredness, seeds of Moringa oleifera for treatment of their chronic illnesses, and mixed vegetable and fruit beverage for diabetes, see Table 4.

Table 4 Reasons why patients decided to use or stop using HDS at the end point (n = 357)
Full size table
Table 5 Herbal and dietary supplements and respondents’ experiences on benefits or adverse effects
Full size table

Two patients were recommended by their doctor to use fish oil for the prevention of cardiovascular disease, vitamin E for CKD and vitamin C for the common cold. Twenty-three percent (n = 10) of those who stopped were advised by their doctor to avoid using HDS, i.e. Thai traditional herbal remedies, Moringa oleifera, rice bran oil, Chinese traditional medicine, curcumin, germ oil and chlorophyll.

Reasons for non-use of HDS at baseline are shown in Table 6. The most frequently cited such reasons were either trust in their doctor or a belief in the benefits from conventional medicine (32%, n = 62), followed by health care professionals’ recommendations to avoid HDS (19%, n = 36). Eight participants (5%) reported that they had no particular reasons for choosing not to use HDS.

Table 6 Reasons for not using HDS at baseline (n = 194) a
Full size table

Discussion

Over the 12 months of the study, most patients continued to use or not use HDS. It is clear that having either an expectation or perception of gaining benefit from using HDS was the most important factor influencing patients with CKD to start or continue using HDS in the present study. These findings are supported by a large number of other surveys in patients with chronic illnesses, including kidney diseases [4, 8, 14, 15]. Several studies in the US, Netherlands and Thailand also report that patients complement their conventional medicine with HDS similar to the findings in the present study [7, 10, 12, 13]. Some patients reported that they wanted to use HDS combined with their conventional medicine for incremental beneficial effects. This suggests that health care professionals and researchers should investigate how to integrate conventional medicine and HDS in order to complement their benefits and avoid detrimental effects in patients with CKD.

Meanwhile, patients who decided to stop, or not use, HDS was largely due to either experiences of adverse effects, a perception of no benefit from using HDS, or having negative attitudes towards HDS. This is consistent with a European survey in cancer patients [21]. In addition, health care professionals’ recommendation for avoiding HDS was a major influence on those who stopped or did not use HDS in the present study. This indicates that health care providers are likely to be a key decision-maker for the group. Further studies need to be investigated regarding the effect of the doctor-patient relationship on patients with CKD and their decision to use HDS or not.

In the current study, patients seemed to be motivated to use HDS as a last resort when they were not satisfied with what conventional medicine could achieve, such as a desire to avoid dialysis therapy [6, 14, 19]. Benefit and safety information about HDS were mainly provided by the media and patients’ family members or friends in the present study. Family members and friends are an influencing factor in patient’s decision-making regarding HDS use in Asian populations. This is supported by other studies of CAM use amongst patients with chronic diseases in Asian countries [2, 7, 8, 22, 33, 34]. This could be a result of the close knit family culture in Asian countries. In comparison with studies in Western countries which found that patients with chronic illnesses used HDS if their health care providers suggested it [4, 10].

A systematic review has shown that the mass media report positive effects of CAM rather than their negative effects [35]. This is similar to our qualitative study where a patient complained about the lack of warning about HDS use in patients with renal insufficiency. Both health care providers and policy makers, particularly in Thailand, should be concerned about the potential impact, and therefore information about both the risks and benefits of using HDS should be widely available, particularly for patients who may be more susceptible to adverse effects from using HDS, such as those with CKD.

It appears that most patients in our study were independent in their decision-making about HDS use as only a small number of patients (6%) used it on the recommendation of their health care provider. Some participants actively searched for information about the benefits and safety of HDS and experimented with HDS by monitoring efficacy and adverse effects. This is likely to be a common process in the decision-making in patients who are interested in alternative therapy [29]. Health care professionals should acknowledge this, and support access to appropriate information for such patients together with monitoring for any effects resulting from HDS use.

Safety of HDS (3%) was seen as less influential on HDS use than their perceived benefit (24%) in our study. Several users were concerned about the potential negative effects of HDS on their kidneys, so they used HDS with caution, such as by reducing the dose of their HDS, or only occasionally using HDS. This differs from Spanner and Duncan’s study (2005) in Canada where they found at least 3 in 4 patients with CKD thought that dietary supplements caused no harm and improved their condition [4]. Likewise, people in the UK perceived that herbal medicine is safer than conventional medicine [36]. It would seem that Thai patients with CKD are more aware of detrimental effects resulting from HDS use and avoid such effects in their own way. Health care providers should be prepared to advise these patients regarding how to safely use HDS.

Amongst patients who reported gaining benefits from using HDS over the 12 months, three quarters perceived that HDS either relieved their minor ailments, such as the common cold, flatulence and constipation, or supplemented their diet. Also, respondents reported that their doctor recommended fish oil for the prevention of cardiovascular disease, vitamin E for CKD, and vitamin C for the common cold. These benefits have been supported by evidence although there is controversy about such beneficial effects from fish oil and vitamin C [37–40]. Vitamin E has been recommended as a vitamin supplement when patients with CKD stage 3 to 5 have a deficit in vitamin E [41].

Respondents perceived that several herbal medicines could maintain their kidney function; however, the majority of studies to prove this effect are in vitro. Hibiscus sabdariffa, cordyceps, Zingiber officinale, shallots, Moringa oleifera, Centella asiatica can inhibit angiotensin converting enzyme, which is related to a decrease in proteinuria, and then to slow the progression of CKD [42–45]. This mechanism also supports Moringa oleifera and Centella asiatica for antihypertensive effects reported by respondents. Moreover, there has been no scientific evidence to support some herbal medicines for maintaining kidney function, such as Zizyphus mauritiana, Boesenbergia rotunda, Clitoria ternatea, Momordica cochinchinensis and Helicteres isora. Therefore, further research, particularly clinical trials, needs to be conducted regarding this issue before any recommendations can be made.

Likewise, Houttuynia cordata and Citrus aurantifolia for diuretic effects have limited evidence in vitro [46, 47]. Clerodendrum petasites has no scientific evidence to support their diuretic effect. In contrast, a randomised, controlled trial with a small number of patients with diabetic type 2 revealed that Momordica charantia decreased glycated haemoglobin (A1C) greater than placebo [48]. This evidence is consistent with respondent’s report.

Almost all adverse effects from using HDS reported by respondents have no further evidence to support their statement. A respondent in the present study found that Thai herbal remedy containing aloe was related to worsening kidney function. This is consistent with a case report; Cape aloe causes acute kidney injury [49]. ‘Luke Klon’ is a dosage form of Thai herbal remedy and may be contaminated with steroids [50], so this product may induce kidney injury. Thus, health care providers and patients should be aware of such detrimental effects.

The findings in this survey should be generalised with caution due to only two hospitals being used as study sites, although the study sample matches the Thai general population in terms of gender, educational level, living in urban or rural areas, smoking and drinking status [51]. Mean age in the current study (66 years) was no different to other studies of patients with CKD in Taiwan, the UK and Italy (65–67 years) [52–54].

Conclusions

Positive attitudes towards herbal and dietary supplements in patients with CKD were the main reasons for HDS use, particularly their perceived benefit. Meanwhile, negative attitudes towards HDS or negative experiences from using HDS, including their doctor’s influence, motivated patients not to use, or to stop, using HDS. The media and patients’ social network seem to positively influence patients to use HDS. Thus, health care providers and policy makers in Thailand should acknowledge this influence and provide high quality information about beneficial and detrimental effects of HDS use for these patients. Further studies are required to investigate the effect of the doctor-patient relationship on decision-making regarding the use of HDS.

References

  1. 1.

    Ernst E: Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000, 78 (2): 252-257.

  2. 2.

    Kara B: Herbal product use in a sample of Turkish patients undergoing haemodialysis. J Clin Nurs. 2009, 18 (15): 2197-2205. 10.1111/j.1365-2702.2008.02730.x.

  3. 3.

    Nowack R, Balle C, Birnkammer F, Koch W, Sessler R, Birck R: Complementary and alternative medications consumed by renal patients in Southern Germany. J Ren Nutr. 2009, 19 (3): 211-219. 10.1053/j.jrn.2008.08.008.

  4. 4.

    Spanner ED, Duncan AM: Prevalence of dietary supplement use in adults with chronic renal insufficiency. J Ren Nutr. 2005, 15 (2): 204-210. 10.1053/j.jrn.2005.01.005.

  5. 5.

    Grabe DW, Garrison GD: Comparison of natural product use between primary care and nephrology patients. Ann Pharmacother. 2004, 38 (7): 1169-1172. 10.1345/aph.1D170.

  6. 6.

    Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A: Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Int Cancer Ther. 2005, 4 (4): 274-286. 10.1177/1534735405282361.

  7. 7.

    Moolasarn S, Sripa S, Kuessirikiet V, Sutawee K, Huasary J, Chaisila C, Chechom N, Sankan S: Usage of and cost of complementary/alternative medicine in diabetic patients. J Med Assoc Thai. 2005, 88 (11): 1630-1637.

  8. 8.

    Hasan SS, Ahmed SI, Bukhari NI, Loon WCW: Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complement Ther Clin Pract. 2009, 15 (3): 152-157. 10.1016/j.ctcp.2009.02.003.

  9. 9.

    Chu FY, Yan X, Zhang Z, Xiong XJ, Wang J, Liu HX: Features of complementary and alternative medicine use by patients with coronary artery disease in Beijing: a cross-sectional study. BMC Complement Altern Med. 2013, 13: 287-10.1186/1472-6882-13-287.

  10. 10.

    Yeh GY, Davis RB, Phillips RS: Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006, 98 (5): 673-680. 10.1016/j.amjcard.2006.03.051.

  11. 11.

    D’Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, Buda A, Sturniolo GC: Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis. 2007, 39 (6): 524-529. 10.1016/j.dld.2007.03.001.

  12. 12.

    Jong MC, van de Vijver L, Busch M, Fritsma J, Seldenrijk R: Integration of complementary and alternative medicine in primary care: what do patients want?. Patient Educ Couns. 2012, 89 (3): 417-422. 10.1016/j.pec.2012.08.013.

  13. 13.

    Kanodia AK, Legedza ATR, Davis RB, Eisenberg DM, Phillips RS: Perceived benefit of complementary and alternative medicine (CAM) for back pain: a national survey. J Am Board Fam Med. 2010, 23 (3): 354-362. 10.3122/jabfm.2010.03.080252.

  14. 14.

    Lambert TD, Morrison KE, Edwards J, Clarke CE: The use of complementary and alternative medicine by patients attending a UK headache clinic. Complement Ther Med. 2010, 18 (3–4): 128-134.

  15. 15.

    Rossi P, Torelli P, Lorenzo CD, Sances G, Manzoni GC, Tassorelli C, Nappi G: Use of complementary and alternative medicine by patients with cluster headache: results of a multi-centre headache clinic survey. Complement Ther Med. 2008, 16 (4): 220-227. 10.1016/j.ctim.2007.05.002.

  16. 16.

    Alshagga MA, Al-Dubai SA, Faiq SSM, Yusuf AA: Use of complementary and alternative medicine among asthmatic patients in primary care clinics in Malaysia. Ann Thorac Med. 2011, 6 (3): 115-119. 10.4103/1817-1737.82438.

  17. 17.

    Shorofi SA: Complementary and alternative medicine (CAM) among hospitalised patients: reported use of CAM and reasons for use, CAM preferred during hospitalisation, and the socio-demographic determinants of CAM users. Complement Ther Clin Pract. 2011, 17 (4): 199-205. 10.1016/j.ctcp.2011.05.001.

  18. 18.

    Vickers KA, Jolly KB, Greenfield SM: Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006, 6: 40-10.1186/1472-6882-6-40.

  19. 19.

    Yu H, Wang S, Liu J, Lewith G: Why do cancer patients use Chinese medicine? - a qualitative interview. Eur J Integr Med. 2012, 4 (2): e197-e203. 10.1016/j.eujim.2012.02.007.

  20. 20.

    Chen W-T, Shiu C-S, Simoni J, Fredriksen-Goldsen K, Zhang F, Starks H, Zhao H: Attitudes toward antiretroviral therapy and complementary and alternative medicine in Chinese patients infected with HIV. J Assoc Nurses AIDS Care. 2009, 20 (3): 203-217. 10.1016/j.jana.2008.12.004.

  21. 21.

    Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AMA, Platin N, Kearney N, Patiraki E: Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005, 16 (4): 655-663. 10.1093/annonc/mdi110.

  22. 22.

    Saw JT, Bahari MB, Ang HH, Lim YH: Herbal use amongst multiethnic medical patients in Penang hospital: pattern and perceptions. Med J Malaysia. 2006, 61 (4): 422-432.

  23. 23.

    Cheung CK, Wyman JF, Halcon LL: Use of complementary and alternative therapies in community-dwelling older adults. J Altern Complement Med. 2007, 13 (9): 997-1006. 10.1089/acm.2007.0527.

  24. 24.

    Shah S, Singh N, Qureshi W: Prevalence of complementary and alternative medicine in patients with chronic kidney disease in India. Am J Kidney Dis. 2013, 61 (4): A88-

  25. 25.

    General guidelines for methodologies on research and evaluation of traditional medicine.http://whqlibdoc.who.int/hq/2000/WHO_EDM_TRM_2000.1.pdf,

  26. 26.

    Overview of dietary supplements.http://www.fda.gov,

  27. 27.

    Tangkiatkumjai M, Boardman H, Praditpornsilpa K, Walker DM: Prevalence of herbal and dietary supplement usage in Thai outpatients with chronic kidney disease: a cross-sectional survey. BMC Complement Altern Med. 2013, 13: 153-10.1186/1472-6882-13-153.

  28. 28.

    Astin JA: Why patients use alternative medicine: results of a national study. JAMA. 1998, 279 (19): 1548-1553. 10.1001/jama.279.19.1548.

  29. 29.

    Caspi O, Koithan M, Criddle MW: Alternative medicine or “alternative” patients: a qualitative study of patient-oriented decision-making processes with respect to complementary and alternative medicine. Med Decis Making. 2004, 24 (1): 64-79. 10.1177/0272989X03261567.

  30. 30.

    Larson ML: Meaning-based translation: a guide to cross-language equivalence. 1998, Oxford: University Press of America, 2

  31. 31.

    Guest G, MacQueen KM, Namey EE: Applied thematic analysis. 2012, California: SAGE Publications, 1

  32. 32.

    Braun V, Clarke V: Using thematic analysis in psychology. Qual Res Psychol. 2006, 3 (2): 77-101. 10.1191/1478088706qp063oa.

  33. 33.

    Moolasarn S, Sripa S, Kuesirikiet V, Sutawee K, Huasary J, Chaisila C, Chuechom N, Sankarn S: Usage of alternative medicine in cancer patients. Siriraj Med J. 2003, 55 (6): 307-323.

  34. 34.

    Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S: Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005, 23 (12): 2645-2654.

  35. 35.

    Weeks LC, Strudsholm T: A scoping review of research on complementary and alternative medicine (CAM) and the mass media: looking back, moving forward. BMC Complement Altern Med. 2008, 8: 43-10.1186/1472-6882-8-43.

  36. 36.

    Lynch N, Berry D: Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med. 2007, 15 (2): 84-91. 10.1016/j.ctim.2006.06.007.

  37. 37.

    National Drug Committee: National list of herbal medicine products. 2011, Bangkok: Ministry of Public Health Thailand, 1

  38. 38.

    Chauhan B, Kumar G, Kalam N, Ansari SH: Current concepts and prospects of herbal nutraceutical: a review. J Adv Pharm Technol Res. 2014, 4 (1): 4-8.

  39. 39.

    Hemila H, Chalker E: Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013, 31 (1): CD000980

  40. 40.

    Superko HR, Superko AR, Lundberg GP, Margolis B, Garrett BC, Nasir K, Agatston AS: Omega-3 fatty acid blood levels clinical significance update. Curr Cardiovasc Risk Rep. 2014, 8 (11): 407-

  41. 41.

    Steiber AL, Kopple JD: Vitamin status and needs for people with stage 3–5 chronic kidney disease. J Ren Nutr. 2011, 21 (5): 355-368. 10.1053/j.jrn.2010.12.004.

  42. 42.

    Ojeda D, Jimenez-Ferrer E, Zamilpa A, Herrera-Arellano A, Tortoriello J, Alvarez L: Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from Hibiscus sabdariffa. J Ethnopharmacol. 2010, 127 (1): 7-10. 10.1016/j.jep.2009.09.059.

  43. 43.

    Shashidhar MG, Giridhar P, Sankar KU, Manohar B: Bioactive principles from Cordyceps sinensis: a potent food supplement - a review. J Funct Foods. 2013, 5 (3): 1013-1030. 10.1016/j.jff.2013.04.018.

  44. 44.

    Somanadhan B, Varughese G, Palpu P, Sreedharan R, Gudiksen L, Smitt UW, Nyman U: An ethnopharmacological survey for potential angiotensin converting enzyme inhibitors from Indian medicinal plants. J Ethnopharmacol. 1999, 65 (2): 103-112. 10.1016/S0378-8741(98)00201-3.

  45. 45.

    Hansen K, Nyman U, Smitt UW, Adsersen A, Gudiksen L, Rajasekharan S, Pushpangadan P: In vitro screening of traditional medicines for anti-hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). J Ethnopharmacol. 1995, 48 (1): 43-51. 10.1016/0378-8741(95)01286-M.

  46. 46.

    Fu J, Dai L, Lin Z, Lu H: Houttuynia cordata Thunb: a review of phytochemistry and pharmacology and quality control. Chin Med. 2013, 4 (3): 101-123. 10.4236/cm.2013.43015.

  47. 47.

    Arias BA, Ramon-Laca L: Pharmacological properties of citrus and their ancient and medieval uses in the Mediterranean region. J Ethnopharmacol. 2005, 97 (1): 89-95. 10.1016/j.jep.2004.10.019.

  48. 48.

    Trakoon-osot W, Sotanaphun U, Phanachet P, Porasuphatana S, Udomsubpayakul U, Komindr S: Pilot study: hypoglycemic and antiglycation activities of bitter melon (Momordica charantia L.) in type 2 diabetic patients. J Pharm Res. 2013, 6 (8): 859-864. 10.1016/j.jopr.2013.08.007.

  49. 49.

    Luyckx VA, Ballantine R, Claeys M, Cuyckens F, Van den Heuvel H, Cimanga RK, Vlietinck AJ, De Broe ME, Katz IJ: Herbal remedy-associated acute renal failure secondary to Cape aloes. Am J Kidney Dis. 2002, 39 (3): E13-E17.

  50. 50.

    Thai Food and Drug Administration: Summary report on the surveillance of health products in 2012. 2013, Bangkok: Thai Food and Drug Administration, 17-18.

  51. 51.

    National statistical office.http://web.nso.go.th/,

  52. 52.

    Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O’Donoghue DJ, Foley RN, Middleton RJ: Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010, 56 (6): 1072-1081. 10.1053/j.ajkd.2010.06.010.

  53. 53.

    Nicola LD, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Lorio BD, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R, for the SIN-TABLE CKD Study Group: Prognosis of CKD patients receiving outptient nephrology care in Italy. Clin J Am Soc Nephrol. 2011, 6 (10): 2421-2428. 10.2215/CJN.01180211.

  54. 54.

    Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD: Outcomes of stage 3–5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract. 2008, 109 (3): c109-c118. 10.1159/000145453.

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/473/prepub

Download references

Acknowledgements

This study was funded by the Royal Thai Government. We would like to thank the patients and their family members who participated in this study and Dr. Charoen Treesak for backward translation. Many Thanks to the doctors, nurses and pharmacists in both King Chulalongkorn Memorial Hospital and HRH Princess Maha Chakri Sirindhorn Medical Center who provided access to their patients.

Author information

Affiliations

  1. Division of Primary Care, School of Medicine, University of Nottingham, QMC, Nottingham, NG7 2UH, UK
    • Mayuree Tangkiatkumjai
    •  & Dawn-Marie Walker
  2. Division of Social Research in Medicines and Health, School of Pharmacy, University of Nottingham, Nottingham, UK
    • Helen Boardman
  3. Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    • Kearkiat Praditpornsilpa
Authors
  1. Mayuree Tangkiatkumjai
    View author publications
    You can also search for this author in
  2. Helen Boardman
    View author publications
    You can also search for this author in
  3. Kearkiat Praditpornsilpa
    View author publications
    You can also search for this author in
  4. Dawn-Marie Walker
    View author publications
    You can also search for this author in

Corresponding author

Correspondence to Mayuree Tangkiatkumjai.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MT conceived the study, performed the analysis, coordination of the study and drafted the manuscript. KP advised on the feasibility of the study and participated in coordination of the study. MT, DMW and HB designed the study, the questionnaire and eight open-ended questions and data analyses. All authors reviewed the manuscript and have read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tangkiatkumjai, M., Boardman, H., Praditpornsilpa, K. et al. Reasons why Thai patients with chronic kidney disease use or do not use herbal and dietary supplements. BMC Complement Altern Med 14, 473 (2014). https://doi.org/10.1186/1472-6882-14-473

Download citation

Keywords

  • Herbal medicine
  • Dietary supplements
  • Reason
  • Chronic kidney disease
  • Thailand

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us